We thank Michaels and Cameron for their interesting letters in which they made a very important distinction in the role of somatostatin and somatostatin analogues in the treatment of diabetic diarrhea as used in our article.1 We humbly accept the correction for using somatostatin and the somatostain analogue, octreotide, interchangeably in our article.Micheals and Cameron are correct in stating that Tsai et al2 used the somatostatin analogue, octreotide, at a dose of 50 to 75 μg (not milligrams) by subcutaneous injection twice a day. We also point out an error in the dose of clonidine as quoted in our article. Clonidine is used at an average daily dose of 0.1 mg (not 1 mg). We apologize for the typographical error.
Ogbonnaya KI, Arem R. Octreotide Is Cost-effective Therapy in Diabetic Diarrhea-Reply. Arch Intern Med. 1991;151(12):2469–2473. doi:10.1001/archinte.1991.00400120103020
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: